Incorporating Centrally Tolerized Mice as a Design Principle to Circumvent Reporter Immunogenicity in Cancer Research...

Area of Science:

• Oncology
• Immunology
• Preclinical Cancer Research

Background:

• Tumor progression and metastasis studies often use immunocompetent mice with reporter-labeled tumor cells.
• Reporter proteins (bioluminescent/fluorescent) can trigger adaptive immune responses, confounding study results.
• Previous work suggested using centrally tolerized mouse strains to control for these artifactual immune responses.

Purpose of the Study:

• To apply a centrally tolerized mouse strain (Tol mouse) to overcome limitations of xenoantigenic reporters in immunocompetent models.
• To demonstrate how immune responses to reporter proteins can confound immunotherapy efficacy studies.
• To highlight the utility of tolerized transgenic models in preclinical cancer research.

Main Methods:

• Utilized the Tol mouse strain, a centrally tolerized model.
• Implanted reporter-labeled tumor cells into immunocompetent settings.
• Evaluated the impact of antigenic responses against reporter proteins on study interpretations.

Main Results:

• Khan and colleagues successfully applied the Tol mouse to mitigate confounding immune responses.
• Antigenic responses against reporter proteins were shown to interfere with immunotherapy efficacy measurements.
• The study confirmed that reporter-induced immune responses can distort preclinical cancer study outcomes.

Conclusions:

• Centrally tolerized transgenic models are valuable for improving preclinical investigations.
• Employing such models enhances the accuracy of cancer metastasis and therapeutic resistance studies.
• This approach provides a more reliable method for evaluating cancer therapies in vivo.